XOMA (NASDAQ:XOMA) Research Coverage Started at SVB Leerink

Equities researchers at SVB Leerink started coverage on shares of XOMA (NASDAQ:XOMA) in a report issued on Monday, Briefing.com reports. The brokerage set an “outperform” rating and a $40.00 price target on the biotechnology company’s stock. SVB Leerink’s price objective points to a potential upside of 57.42% from the company’s previous close.

Separately, HC Wainwright reiterated a “buy” rating and issued a $74.00 price objective on shares of XOMA in a report on Thursday.

XOMA Price Performance

XOMA opened at $25.41 on Monday. The company has a market capitalization of $295.77 million, a price-to-earnings ratio of -6.29 and a beta of 0.58. The company has a quick ratio of 8.68, a current ratio of 8.68 and a debt-to-equity ratio of 1.34. The firm has a 50-day moving average price of $24.91 and a 200-day moving average price of $20.48. XOMA has a twelve month low of $13.48 and a twelve month high of $27.00.

XOMA (NASDAQ:XOMA) last announced its quarterly earnings results on Friday, March 8th. The biotechnology company reported ($0.49) EPS for the quarter, missing the consensus estimate of ($0.36) by ($0.13). The firm had revenue of $1.83 million during the quarter, compared to the consensus estimate of $1.01 million. XOMA had a negative net margin of 886.91% and a negative return on equity of 25.17%. Equities analysts expect that XOMA will post -1.73 EPS for the current year.

Institutional Investors Weigh In On XOMA

An institutional investor recently raised its position in XOMA stock. Stonepine Capital Management LLC grew its stake in shares of XOMA Co. (NASDAQ:XOMA) by 25.0% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 436,602 shares of the biotechnology company’s stock after purchasing an additional 87,203 shares during the quarter. XOMA makes up approximately 2.0% of Stonepine Capital Management LLC’s investment portfolio, making the stock its 12th largest position. Stonepine Capital Management LLC owned approximately 3.80% of XOMA worth $6,152,000 as of its most recent filing with the Securities and Exchange Commission. 95.92% of the stock is owned by institutional investors and hedge funds.

About XOMA

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.